-+ 0.00%
-+ 0.00%
-+ 0.00%

NeOnc wins UAE IND clearance for brain cancer drug NEO212

PUBT·06/16/2026 13:01:04
Listen to the news
NeOnc wins UAE IND clearance for brain cancer drug NEO212
  • NeOnc Technologies won UAE IND clearance from the Department of Health – Abu Dhabi for NEO212, enabling Phase 2 clinical evaluation.
  • The oral perillyl alcohol–temozolomide conjugate recently completed Phase 1 dose escalation, setting a 610 mg recommended Phase 2 dose.
  • The approval adds an international clinical pathway alongside ongoing U.S. FDA talks on a potential registrational strategy for NEO212.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160900PRIMZONEFULLFEED9747441) on June 16, 2026, and is solely responsible for the information contained therein.